Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 18 (4), 163-76

Insomnia Causes, Consequences, and Therapeutics: An Overview


Insomnia Causes, Consequences, and Therapeutics: An Overview

Christopher L Drake et al. Depress Anxiety.


There is growing interest in insomnia both from the perspective of recent advances in clinical management as well as research aimed at elucidating its pathophysiology. This theoretical overview of insomnia describes the negative impact, etiological considerations, and pharmacological and behavioral treatments for the disorder, with an emphasis on areas receiving increased research attention. Insomnia, the most prevalent sleep disorder, affects 10-15% of the general population. In population-based studies severe insomnia has been shown to last for a median of 4 years. In addition, insomnia has a significant negative impact on an individual's work, physical, and social performance as well as overall quality of life. Furthermore, the economic cost of insomnia related to lost productivity, work-related accidents, absenteeism, and health-care costs are enormous. There is increasing evidence linking the precipitation of insomnia to stress, and converging evidence from cognitive, endocrine, neurological, and behavioral domains provide clear evidence for hyper-arousal in insomnia. However, there remains no consensus regarding the specific etiological mechanisms of this disorder. Although the pathophysiology of primary insomnia remains an enigma, numerous treatments both pharmacological and behavioral have been developed and found to be efficacious in controlled studies. Despite the wide availability of pharmacological treatments and increased knowledge of behavioral interventions, the vast majority of individuals with insomnia do not appear to be receiving adequate treatment. The inadequate treatment of insomnia leads to several important and under-recognized consequences including subsequent development of psychiatric disease and increased substance use.

Similar articles

  • Prevalence, Associated Risks, and Treatment Patterns of Insomnia
    T Roth. J Clin Psychiatry 66 Suppl 9, 10-3; quiz 42-3. PMID 16336036. - Review
    Insomnia, the most commonly reported sleep problem, affects about one third of the adult American population. Insomnia impairs the individual's functioning, diminishes hi …
  • [Insomnia]
    JP Doerr et al. Med Monatsschr Pharm 31 (9), 339-45. PMID 18831465. - Review
    Insomnia is a highly prevalent disorder with consequences for the patient's physical and mental health, daily function, and job performance. This paper gives an overview …
  • The State of Insomnia and Emerging Trends
    T Roth et al. Am J Manag Care 13 (5 Suppl), S117-20. PMID 18041871. - Review
    Recent research into the pathophysiology of insomnia has brought a shift in the approach to treatment. Insomnia rarely occurs in isolation and is typically comorbid with …
  • Pharmacologic Management of Insomnia
    JK Walsh. J Clin Psychiatry 65 Suppl 16, 41-5. PMID 15575804. - Review
    Pharmacotherapy is indicated for many types of insomnia, most notably transient insomnia associated with stress, acute illness, or jet lag. Many patients with chronic ins …
  • Practice Parameters for the Psychological and Behavioral Treatment of Insomnia: An Update. An American Academy of Sleep Medicine Report
    T Morgenthaler et al. Sleep 29 (11), 1415-9. PMID 17162987.
    Insomnia is highly prevalent, has associated daytime consequences which impair job performance and quality of life, and is associated with increased risk of comorbidities …
See all similar articles

Cited by 60 PubMed Central articles

See all "Cited by" articles

MeSH terms

LinkOut - more resources